Genomind

Genomind is a precision medicine company that develops genetics-based medication management tools for patients, healthcare providers, accountable care organizations (ACOs), employers, and health plans. Founded over a decade ago by psychiatrist Dr. Ronald Dozoretz, the company began as one of the first mental health-focused pharmacogenetic testing services and has since expanded its platform to cover a broader range of conditions. Genomind's core approach pairs a provider's clinical expertise with a patient's genetic profile, lifestyle, and environment to move away from trial-and-error prescribing toward personalized, targeted treatment decisions. The platform is used by nearly 20,000 health providers serving more than 400,000 patients.

Genomind's mission is to optimize the treatment experience for individuals and healthcare providers by making actionable genetic insights and health technology accessible. The company points to significant systemic problems its platform is designed to address: 3.2 million hospital and emergency room visits per year are attributed to adverse drug events (the fourth leading cause of death in the US), more than 50% of patients are non-adherent to medications due to side effects or lack of efficacy, annual costs from wrong drugs, incorrect doses, and drug interactions exceed $528 billion, and 52% of outpatient adverse drug events are considered preventable.

Core Products and Services

• Pharmacogenetic (PGx) Testing: Assesses a patient's genetics to personalize dosing and medication choices, helping providers select the most appropriate drug and dose for an individual.
• Precision Medicine Software: Identifies gene-drug and drug-drug interaction risks and dynamically adjusts recommendations toward safer alternatives within an integrated platform.
• Precision Medicine Consults: Provides access to PharmD and PhD experts for staff training, clinical consultations, and related support services.
• Population Health Assessment: Stratifies patient populations based on risk for drug-drug and gene-drug interactions, enabling large-scale medication management with precision.

Platform Capabilities

• Assessment of drug-drug, gene-drug, and drug-drug-gene interactions to support safer and more targeted treatment approaches.
• Management of medications for both individual patients and large patient populations within a single integrated platform.
• Association with reducing hospitalizations and individual healthcare costs.
• Support for the quadruple aim of care for ACOs, improved employee health and productivity for employers, and cost reduction and outcome improvement for health plans.
• An education platform called Genomind 360, offering in-person, virtual, and self-paced learning on precision medicine topics.

Notable Partnerships, Contracts, and Recognition

• Genomind has been awarded a contract by the Department of Defense to support pharmacogenomics consulting.
• The company has partnered with Evexia Diagnostics to expand access to its pharmacogenetic testing for clinicians.
• Genomind has conducted outreach to nursing home and long-term care settings, offering genetics-based medication management for residents with mental health conditions such as schizophrenia and dementia-related symptoms.
• The company has received several awards, including recognition as one of the highest-valued startups by the Philadelphia Business Journal (2021, #16), Best Biotech Company to Work by MedRep (2020 and 2017), #2655 on the Inc. 5000 list of fastest-growing private companies in America (2018), a Philadelphia 100 Award for top 100 fastest-growing privately held companies (2018), and placement on Deloitte's Technology Fast 500 (2017, #454).

Genomind's heritage is rooted in mental health pharmacogenetics, but the company has broadened its scope to address a wider range of clinical conditions. Its platform is designed to reduce guesswork in prescribing, lower preventable adverse drug events, and improve satisfaction for both patients and healthcare providers.